Mar 29, 2018   SOURCE: PR NewsWire

TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

Company to Provide Corporate and Clinical Overview on Thursday, April 5, 2018, 4:30pm ET

JACKSONVILLE, Fla., March 29, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that the Company will host a conference call and live audio webcast on Thursday, April 5, 2018, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2017.

Reserve Your Seat: Register Today
The event will be webcast live via the Internet on:

April 5, 2018
4:30 PM ET

Click here to register today, or visit https://tapimmune.com/register

Day-of Call-in Information:
To access the live conference call on April 5, 2018, at 4:30pm ET you may use:

    --  (855) 238-2333 (U.S.)
    --  (412) 317-5215 (International)

To access the live audio webcast, visit the Events section of the TapImmune website: http://tapimmune.com/events. The webcast will also be archived for 90 days beginning at approximately 6:30 p.m. ET, on April 5, 2018.

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be used without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.

For additional information visit: https://tapimmune.com/

To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/

CONTACT: Tiberend Strategic Advisors, Inc., Joshua Drumm, Ph.D. (Investors), (212) 375-2664, jdrumm@tiberend.com; David Schemelia (Media), (212) 375-2686, dschemelia@tiberend.com; TapImmune Inc., Aaron Santos, (904) 862-6490 ext. 102, asantos@tapimmune.com

View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-provide-fourth-quarter-and-full-year-2017-business-update-conference-call-and-webcast-300621358.html

SOURCE TapImmune Inc.